Screener
Krystal Biotech, Inc. KRYS EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Krystal Biotech, Inc.’s reported figures.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026. Open the filing →
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
FAQ
- What is Krystal Biotech, Inc.'s EBITDA?
- Krystal Biotech, Inc. (KRYS) reported EBITDA of $55.21M in Q1 2026.
- How has Krystal Biotech, Inc.'s EBITDA changed year-over-year?
- Krystal Biotech, Inc.'s EBITDA increased by 46.6% year-over-year, from $37.66M to $55.21M.
- What is the long-term trend for Krystal Biotech, Inc.'s EBITDA?
- Over 4 years (2021 to 2025), Krystal Biotech, Inc.'s EBITDA has grown at a 26.3% compound annual growth rate (CAGR), from -$65.51M to $166.88M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Krystal Biotech, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude